This is a non-core endpoint: only basic statistics are computed.
Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
Q17_CONGEN_MALFO_SYNDR_KNOWN_EXOGE_CAUSES_NOT_ELSEW_CLASSIFIED
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
40
Check minimum number of events None
40
Include endpoints None
40
Remove individuals based on genotype QC
36
Q17_CONGEN_MALFO_SYNDR_KNOWN_EXOGE_CAUSES_NOT_ELSEW_CLASSIFIED
Control definitions
Control exclude
Q17_OTHER_CONGEN_MALFO
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q8
Name in latin
Syndromata malformationum congenitarum e causis externis notis non alibi classificata
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
based on the number of shared cases.
Broader endpoints:
- Exclusion endpoint for clefts
- Other congenital malformations
- Congenital malformations, deformations and chromosomal abnormalities
- Any event in hilmo or specialist outpatient
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 36 | 18 | 18 |
| Unadjusted prevalence (%) | 0.01 | 0.01 | 0.01 |
| Mean age at first event (years) | 25.83 | 17.08 | 34.58 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: Q17_CONGEN_MALFO_SYNDR_KNOWN_EXOGE_CAUSES_NOT_ELSEW_CLASSIFIED – Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
↥Endpoint not on priority list, no data to show.